These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Paradoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: quantitative image analysis. Fujita M; Yamamoto R; Takahashi M; Tsuji T; Yamanaka T; Miyazawa T; Fritz-Zieroth B; Terada N; Kuroda C J Magn Reson Imaging; 1997; 7(4):768-70. PubMed ID: 9243401 [TBL] [Abstract][Full Text] [Related]
23. Contrast-enhanced MR cholangiography: comparison of Gd-EOB-DTPA and Mn-DPDP in healthy volunteers. Bae K; Na JB; Choi DS; Cho JM; Choi HC; Jeon KN; Park MJ; Choi HY; Kim JE; Chung SH Br J Radiol; 2012 Sep; 85(1017):1250-4. PubMed ID: 22553292 [TBL] [Abstract][Full Text] [Related]
24. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011 [TBL] [Abstract][Full Text] [Related]
25. Potential for differential diagnosis with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors. Tsuda N; Kato N; Murayama C; Narazaki M; Yokawa T Invest Radiol; 2004 Feb; 39(2):80-8. PubMed ID: 14734922 [TBL] [Abstract][Full Text] [Related]
26. Comparison of gadolinium-DTPA and polylysine-gadolinium-DTPA--enhanced magnetic resonance imaging of hepatocarcinoma in the rat. Grandin C; Van Beers BE; Demeure R; Goudemant JF; Mottet I; Pringot J Invest Radiol; 1995 Oct; 30(10):572-81. PubMed ID: 8557496 [TBL] [Abstract][Full Text] [Related]
27. Influence of gadolinium chelates on phosphorus-31 magnetic resonance spectroscopy of the liver. Bauer H; Negishi C; Weinmann HJ Invest Radiol; 1994 Aug; 29(8):752-7. PubMed ID: 7960625 [TBL] [Abstract][Full Text] [Related]
28. Gadolinium-ethoxybenzyl-DTPA, a new liver-directed magnetic resonance contrast agent. Absence of acute hepatotoxic, cardiovascular, or immunogenic effects. Mühler A; Clément O; Saeed M; Lake JR; Stites DP; Berthezène Y; Brasch RC Invest Radiol; 1993 Jan; 28(1):26-32. PubMed ID: 8425849 [TBL] [Abstract][Full Text] [Related]
29. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA. Saito S; Obata A; Kashiwagi Y; Abe K; Murase K Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774 [TBL] [Abstract][Full Text] [Related]
30. Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats. Mühler A; Heinzelmann I; Weinmann HJ Invest Radiol; 1994 Feb; 29(2):213-6. PubMed ID: 8169100 [TBL] [Abstract][Full Text] [Related]
31. The relaxivity of Gd-EOB-DTPA and Gd-DTPA in liver and kidney of the Wistar rat. Shuter B; Tofts PS; Wang SC; Pope JM Magn Reson Imaging; 1996; 14(3):243-53. PubMed ID: 8725190 [TBL] [Abstract][Full Text] [Related]
32. Hepatic kinetics and magnetic resonance imaging of gadolinium ethoxybenzyl diethylenetriaminepentacetic acid (Gd-EOB-DTPA) in dogs. Benness G; Khangure M; Morris I; Warwick A; Burrows P Australas Radiol; 1993 Aug; 37(3):252-5. PubMed ID: 8373327 [TBL] [Abstract][Full Text] [Related]
34. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Giovagnoni A; Paci E Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717 [TBL] [Abstract][Full Text] [Related]
35. Comparison of Gd-Bz-TTDA, Gd-EOB-DTPA, and Gd-BOPTA for dynamic MR imaging of the liver in rat models. Jaw TS; Chen SH; Wang YM; Hsu JS; Kuo YT; Chiu YY; Tsai KB; Hsieh TJ; Liu GC Kaohsiung J Med Sci; 2012 Mar; 28(3):130-7. PubMed ID: 22385605 [TBL] [Abstract][Full Text] [Related]
36. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. Runge VM J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461 [TBL] [Abstract][Full Text] [Related]
37. Liposomal Gd-DTPA: effect of encapsulation on enhancement of hepatoma model by MRI. Unger EC; MacDougall P; Cullis P; Tilcock C Magn Reson Imaging; 1989; 7(4):417-23. PubMed ID: 2811620 [TBL] [Abstract][Full Text] [Related]
38. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Saito K; Kotake F; Ito N; Ozuki T; Mikami R; Abe K; Shimazaki Y Magn Reson Med Sci; 2005; 4(1):1-9. PubMed ID: 16127248 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Schuhmann-Giampieri G; Frenzel T; Schmitt-Willich H Arzneimittelforschung; 1993 Aug; 43(8):927-31. PubMed ID: 8216456 [TBL] [Abstract][Full Text] [Related]
40. Therapy response assessment after radioembolization of patients with hepatocellular carcinoma--comparison of MR imaging with gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid and gadobutrol. Schelhorn J; Best J; Reinboldt MP; Gerken G; Ruhlmann M; Lauenstein TC; Antoch G; Kinner S J Vasc Interv Radiol; 2015 Jul; 26(7):972-9. PubMed ID: 25937296 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]